News | May 28, 2025
Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Subscribe To Our Newsletter & Stay Updated
